WallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for VRTX

Based on 16 analysts offering 12 month price targets for Vertex Pharmaceuticals Inc.
Min Forecast
$200.00+6.18%
Avg Forecast
$266.06+41.25%
Max Forecast
$331.00+75.73%

Should I buy or sell VRTX stock?

Strong Buy
Strong Buy
8 analysts 50%
Buy
5 analysts 31.25%
Hold
3 analysts 18.75%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

VRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Edward Tenthoff
Piper Sandler
Strong BuyMaintains$261.00+38.56%2021-06-14
Robyn Karnauskas
Truist Securities
Strong BuyMaintains$331.00+75.73%2021-06-14
Mohit Bansal
Citigroup
Strong BuyMaintains$285.00+51.31%2021-06-11
Anonymous
Goldman Sachs
Strong BuyMaintains$307.00+62.99%2021-06-11
Alethia Young
Cantor Fitzgerald
Strong BuyMaintains$281.00+49.18%2021-06-11
Paul Matteis
Stifel Nicolaus
Strong BuyMaintains$244.00+29.54%2021-06-11
Gena Wang
Barclays
Strong BuyMaintains$285.00+51.31%2021-06-11
Colin Bristow
UBS
Strong BuyInitiates Coverage On$287.00+52.37%2020-10-28
Brian Skorney
Baird
BuyMaintains$240.00+27.42%2021-06-11
Brian Abrahams
RBC Capital
BuyMaintains$242.00+28.48%2021-06-11

1 of 2

Forecast return on equity

Is VRTX forecast to generate an efficient return?
Company
37.99%
Industry
4.87%
Market
61.45%
VRTX's Return on Equity is forecast to be high in 3 years (37.99%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is VRTX forecast to generate an efficient return on assets?
Company
28.16%
Industry
7.64%
Market
19.05%
VRTX is forecast to generate higher Return on Assets (28.16%) than the US Biotechnology industry average (7.64%)
Forecast

VRTX earnings per share forecast

What is VRTX's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$9.42-11.51%
Avg 2 year Forecast
$10.33-2.9%
Avg 3 year Forecast
$12.29+15.51%
VRTX's earnings are forecast to grow at a rate of 3.06% per year, which is not exceptional
Forecast

VRTX revenue forecast

What is VRTX's revenue in the next 3 years based on estimates from 9 analysts?
Avg 1 year Forecast
$6.9B+7.8%
Avg 2 year Forecast
$7.6B+18.17%
Avg 3 year Forecast
$8.3B+28.63%
VRTX's revenue is forecast to grow at a rate of 8.75% per year, which is not exceptional
Forecast

VRTX earnings growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
3.06%
Industry
28.73%
Market
19.61%
VRTX's earnings are forecast to grow slower (3.06% per year) than the US Biotechnology industry average (28.73%)
Forecast
VRTX's earnings are forecast to grow slower (3.06% per year) than the US market average (19.61%)
Forecast
VRTX's earnings are forecast to grow faster (3.06% per year) than the risk-free savings rate (1.5%)
Forecast

VRTX revenue growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
8.75%
Industry
54.18%
Market
14.6%
VRTX's revenues are forecast to grow slower (8.75% per year) than the US Biotechnology industry average (54.18%)
Forecast
VRTX's revenues are forecast to grow slower (8.75% per year) than the US market average (14.6%)
Forecast

Vertex Pharmaceuticals Stock Forecast FAQ

Is Vertex Pharmaceuticals Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: VRTX) stock is to Strong Buy VRTX stock.

Out of 16 analysts, 8 (50%) are recommending VRTX as a Strong Buy, 5 (31.25%) are recommending VRTX as a Buy, 3 (18.75%) are recommending VRTX as a Hold, 0 (0%) are recommending VRTX as a Sell, and 0 (0%) are recommending VRTX as a Strong Sell.

What is VRTX's earnings growth forecast for 2021-2023?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual earnings growth rate of 3.06% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 28.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.61%.

Vertex Pharmaceuticals's earnings in 2021 is $2,762,032,000.On average, 8 Wall Street analysts forecast VRTX's earnings for 2021 to be $2,437,220,292, with the lowest VRTX earnings forecast at $1,726,634,026, and the highest VRTX earnings forecast at $2,588,656,710. On average, 8 Wall Street analysts forecast VRTX's earnings for 2022 to be $2,674,418,907, with the lowest VRTX earnings forecast at $2,197,769,547, and the highest VRTX earnings forecast at $2,935,536,709.

In 2023, VRTX is forecast to generate $3,181,459,097 in earnings, with the lowest earnings forecast at $3,181,459,097 and the highest earnings forecast at $3,181,459,097.

What is VRTX's revenue growth forecast for 2021-2023?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 8.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 54.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.6%.

Vertex Pharmaceuticals's revenue in 2021 is $6,414,881,000.On average, 9 Wall Street analysts forecast VRTX's revenue for 2021 to be $1,790,197,714,487, with the lowest VRTX revenue forecast at $1,767,389,319,081, and the highest VRTX revenue forecast at $1,824,254,858,761. On average, 10 Wall Street analysts forecast VRTX's revenue for 2022 to be $1,962,260,030,956, with the lowest VRTX revenue forecast at $1,889,530,426,360, and the highest VRTX revenue forecast at $2,048,921,785,965.

In 2023, VRTX is forecast to generate $2,135,961,484,854 in revenue, with the lowest revenue forecast at $1,967,896,830,942 and the highest revenue forecast at $2,368,646,776,217.

What is VRTX's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: VRTX) forecast ROA is 28.16%, which is higher than the forecast US Biotechnology industry average of 7.64%.

What is VRTX's Price Target?

According to 16 Wall Street analysts that have issued a 1 year VRTX price target, the average VRTX price target is $266.06, with the highest VRTX stock price forecast at $331.00 and the lowest VRTX stock price forecast at $200.00.

On average, Wall Street analysts predict that Vertex Pharmaceuticals's share price could stay at $266.06 by Jun 14, 2022. The average Vertex Pharmaceuticals stock price prediction forecasts a potential downside of N/A from the current VRTX share price of $188.36.

What is VRTX's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: VRTX) Vertex Pharmaceuticals's current Earnings Per Share (EPS) is $10.64. On average, analysts forecast that VRTX's EPS will be $9.42 for 2021, with the lowest EPS forecast at $6.67, and the highest EPS forecast at $10.00. On average, analysts forecast that VRTX's EPS will be $10.33 for 2022, with the lowest EPS forecast at $8.49, and the highest EPS forecast at $11.34. In 2023, VRTX's EPS is forecast to hit $12.29 (min: $12.29, max: $12.29).

What is VRTX's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: VRTX) forecast ROE is 37.99%, which is considered strong.
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.